Green pharmacy and pharmEcovigilance: Prescribing and the planet

Expert Review of Clinical Pharmacology

Volumn 4, Issue 2, 2011, Pages 211-232

  Daughton, Christian G ^a   Ruhoy, Ilene S ^b,c  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b TOURO UNIVERSITY NEVADA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

APIs; disposal; environmental contamination; evidence based prescribing; personalized medicine; pharmaceuticals; pollution prevention; sustainability; US EPA; wastewater

Indexed keywords

ACTIVE PHARMACEUTICAL INGREDIENT; ANTIBIOTIC AGENT; CARBAMAZEPINE; CLOFIBRIC ACID; DICLOFENAC; ENVIRONMENTAL CHEMICAL; ESTROGEN; ETHINYLESTRADIOL; FINASTERIDE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; IOPAMIDOL; IOPROMIDE; MEPROBAMATE; METHOTREXATE; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENTOBARBITAL; PHENAZONE; PHENYTOIN; SEROTONIN UPTAKE INHIBITOR; SULFAMETHOXAZOLE; SULFANILAMIDE DERIVATIVE; TAMOXIFEN; TRICLOSAN; UNCLASSIFIED DRUG;

ANIMAL WELFARE; ARTICLE; DRUG EXCRETION; DRUG MECHANISM; DRUG UTILIZATION; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL IMPACT; ENVIRONMENTAL MONITORING; ENVIRONMENTAL PROTECTION; HUMAN; INFLAMMATION; NONHUMAN; PHARMACEUTICAL CARE; POLLUTION CONTROL; POLLUTION MONITORING; POLYPHARMACY; PRESCRIPTION; RECYCLING; SEWAGE TREATMENT PLANT; TRANSDERMAL PATCH; WASTE DISPOSAL; WATER CONTAMINATION;

ANIMALS; DRUG PRESCRIPTIONS; ENVIRONMENTAL POLLUTANTS; ENVIRONMENTAL POLLUTION; GREEN CHEMISTRY TECHNOLOGY; HUMANS; PHARMACOVIGILANCE; PHARMACY;

EID: 79952752854     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.11.6     Document Type: Article

References (95)

1. Daughton CG, Ruhoy IS. The afterlife of drugs and the role of pharmEcovigilance. Drug Saf. 31(12), 1069-1082 (2008). Seminal article on the concept of the pharmEcovigilance and environmental stewardship of drugs.
2. Daughton CG. Pharmaceuticals as environmental pollutants: the ramifications for human exposure. In:International Encyclopedia of Public Health. Heggenhougen K, Quah S (Eds). Academic Press, Oxford, UK, 66-102 (2008).
3. Leggett R, Lee-Smith EE, Jickells SM, Russell DA. "Intelligent" fingerprinting: simultaneous identification of drug metabolites and individuals by using antibody-functionalized nanoparticles. Angew. Chem. Int. Ed. 46(22), 4100-4103 (2007).
4. Daughton CG, Ruhoy IS. Environmental footprint of pharmaceuticals - the significance of factors beyond direct excretion to sewers. Environ. Toxicol. Chem. 28(12), 2495-2521 (2009). Roles played by disposal, metabolism and excretion in the occurrence of drug residues in the environment.
5. Daughton CG. Environmental stewardship and drugs as pollutants. Lancet 360(9339), 1035-1036 (2002).
6. Daughton CG, Brooks BW. Active pharmaceutical ingredients and aquatic organisms. In:Environmental Contaminants in Biota: Interpreting Tissue Concentrations. Beyer WN, Meador JP (Eds). Taylor and Francis, Boca Raton, FL, USA 281-340 (2011). Comprehensive review of the occurrence and ramifications of drug residues in aquatic biota.
7. Daughton CG. Groundwater recharge and chemical contaminants: challenges in communicating the connections and collisions of two disparate worlds. Ground Water Monit. Remediat. 24(2), 127-138 (2004).
8. Daughton CG. Pharmaceutical ingredients in drinking water: overview of occurrence and significance of human exposure. In:Contaminants of Emerging Concern in the Environment: Ecological and Human Health Considerations. Halden RU (Ed.) ACS Symposium Series 1048, American Chemical Society, Washington, DC, USA 9-68 (2010). Comprehensive review of the occurrence and ramifications of drug residues in drinking water.
9. Gallagher LG, Webster TF, Aschengrau A, Vieira VM. Using residential history and groundwater modeling to examine drinking water exposure and breast cancer. Environ. Health Perspect. 118(6), 749-755 (2010).
10. Wu C, Spongberg AL, Witter JD, Fang M, Czajkowski KP. Uptake of pharmaceutical and personal care products by soybean plants from soils applied with biosolids and irrigated with contaminated water. Environ. Sci. Technol. 44(16), 6157-6161 (2010). Residues of drugs in sewage sludge can be taken up by crops.
11. Langdon KA, Warne MSJ, Kookana RS. Aquatic hazard assessment for pharmaceuticals, personal care products and endocrine disrupting compounds from biosolids-amended land. Integr. Environ. Assess. Manage. 6(4), 663-676 (2010).
12. Blanco G, Lemus JÁ, Martínez F, Arroyo B, García-Montijano M, Grande J. Ingestion of multiple veterinary drugs and associated impact on vulture health: implications of livestock carcass elimination practices. Anim. Conserv. 12(6), 571-580 (2009). Drugs can have profound, unanticipated adverse effects on wildlife.
13. Kümmerer K. Pharmaceuticals in the environment. Annu. Rev. Environ. Resour. 35, 57-75 (2010).
14. Corcoran J, Winter MJ, Tyler CR. Pharmaceuticals in the aquatic environment: a critical review of the evidence for health effects in fish. Crit. Rev. Toxicol. 40(4), 287-304 (2010).
15. Daughton CG, Ternes TA. Pharmaceuticals and personal care products in the environment: agents of subtle change? Environ. Health Perspect. 107(Suppl. 6), 907-938 (1999).
16. Daughton CG. Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health. I. Rationale for and avenues toward a green pharmacy. Environ. Health Perspect. 111(5), 757-774 (2003). Seminal article on the concept of the green pharmacy and environmental stewardship of drugs.
17. Daughton CG. Chemicals from the practice of healthcare: challenges and unknowns posed by residues in the environment. Environ. Toxicol. Chem. 28(12), 2490-2494 (2009).
18. Wishart DS, Knox C, Guo AC et al. DrugBank: a knowledge base for drugs, drug actions and drug targets. Nucleic Acids Res. 36(Suppl. 1), D901-D906 (2008).
19. Kolpin DW, Furlong ET, Meyer MT et al. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance. Environ. Sci. Technol. 36(6), 1202-1211 (2002). Seminal article on the first nationwide monitoring study of drug residues in surface waters.
20. Ramirez AJ, Brain RA, Usenko S et al. Occurrence of pharmaceuticals and personal care products (PPCPs) in fish: results of a national pilot study in the U.S. Environ. Toxicol. Chem. 28(12), 2587-2597 (2009).
21. Boxall AB, Johnson P, Smith EJ, Sinclair CJ, Stutt E, Levy LS. Uptake of veterinary medicines from soils into plants. J. Agric. Food Chem. 54(6), 2288-2297 (2006).
22. Boonsaner M, Hawker DW. Accumulation of oxytetracycline and norfloxacin from saline soil by soybeans. Sci. Total Environ. 408(7), 1731-1737 (2010).
23. Grote M, Schwake-Anduschus C, Michel R et al. Incorporation of veterinary antibiotics into crops from manured soil. Landbauforschung Volkenrode 57(1), 25-32 (2007).
24. Winker M, Clemens J, Reich M, Gulyas H, Otterpohl R. Ryegrass uptake of carbamazepine and ibuprofen applied by urine fertilization. Sci. Total Environ. 408(8), 1902-1908 (2010).
25. Kinney CA, Furlong ET, Kolpin DW et al. Bioaccumulation of pharmaceuticals and other anthropogenic waste indicators in earthworms from agricultural soil amended with biosolid or swine manure. Environ. Sci. Technol. 42(6), 1863-1870 (2008).
26. De Lange HJ, Noordoven W, Murk AJ, Lurling M, Peeters ETHM. Behavioural responses of Gammarus pulex (Crustacea, Amphipoda) to low concentrations of pharmaceuticals. Aquat. Toxicol. 78(3), 209-216 (2006).
27. Guler Y, Ford AT. Anti-depressants make amphipods see the light. Aquat. Toxicol. 90(3), 397-404 (2010).
28. Kidd KA, Blanchfield PJ, Mills KH et al. Collapse of a fish population after exposure to a synthetic estrogen. Proc. Natl Acad. Sci. 104(21), 8897-8901 (2007). Seminal article on the adverse effects of a trace levels of a drug (ethynylestradiol) on sustainability of fish populations.
29. Daughton CG. Emerging chemicals as pollutants in the environment: a 21st century perspective. Renewable Resources J. 23(4), 6-23 (2005).
30. Keil F. Pharmaceuticals for human use: an integrated strategy for reducing the contamination of water bodies. In:Green and Sustainable Pharmacy. Kümmerer K, Hempel M (Eds). Springer-Verlag, Berlin Heidelberg, Germany, 225-241 (2010).
31. Enick OV, Moore MM. Assessing the assessments: pharmaceuticals in the environment. Environ. Impact Assess. Rev. 27(8), 707-729 (2007).
32. Martin OV, Voulvoulis N. Sustainable risk management of emerging contaminants in municipal wastewaters. Philos. Transact. A Math. Phys. Eng. Sci. 367(1904), 3895-3922 (2009).
33. Anon. Rational use of medicines. Lancet 375(9731), 2052 (2010).
34. Wennmalm Å, Gunnarsson B. Pharmaceutical management through environmental product labeling in Sweden. Environ. Int. 35(5), 775-777 (2009).
35. Zuccato E, Calamari D, Natangelo M, Fanelli R. Presence of therapeutic drugs in the environment. Lancet 355(9217), 1789-1790 (2000).
36. Reiter L, Falk H, Groat C, Coussens CM (Eds). From Source Water to Drinking Water: Workshop Summary, National Academies Press, Washington, DC, USA, 126 (2004).
37. Jacobziner H, Raybin HW. Improper disposal of drugs and household products. NY State J. Med. 59, 3631-3634 (1959).
38. Nicholson WA. Collection of unwanted drugs from private homes. Br. Med. J. 3(5567), 730-731 (1967).
39. Grady D, Redberg RF. Less is more: how less health care can result in better health. Arch. Intern. Med. 170(9), 749-750 (2010).
40. Wright GD. Q&A: Antibiotic resistance: where does it come from and what can we do about it? BMC Biol. 8(1), 123 (2010).
41. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl Acad. Sci. DOI: 10.1073/pnas.1000087107 (2010) (Epub ahead of print).
42. Cerf-Bensussan N, Gaboriau-Routhiau V. The immune system and the gut microbiota: friends or foes? Nat. Rev. Immunol. 10(10), 735-744 (2010).
43. Drug Enforcement Administration. Disposal of controlled substances by persons not registered with the drug enforcement administration [Advance Notice of Proposed Rulemaking]. Fed. Regist. 74(12), 3480-3487 (2009).
44. Delbanco T, Walker J, Darer JD et al. Open notes: doctors and patients signing on. Ann. Intern. Med. 153(2), 121-125 (2010).
45. Dentzer S. Thematic issue: comparative effectiveness research. Health Aff. 29(10), 1756-1919 (2010).
46. Barman I, Kong C-R, Singh GP, Dasari RR, Feld MS. Accurate spectroscopic calibration for noninvasive glucose monitoring by modeling the physiological glucose dynamics. Anal. Chem. 82(14), 6104-6114 (2010).
47. James TH, Helms ML, Braund R. Analysis of medications returned to community pharmacies. Ann. Pharmacother. 43(10), 1631-1635 (2009).
48. Daughton CG, Ruhoy IS. Reducing the ecological footprint of pharmaceutical usage: linkages between healthcare practices and the environment. In:Green and Sustainable Pharmacy. Kümmerer K, Hempel M (Eds). Springer-Verlag, Berlin Heidelberg, Germany, 77-102 (2010).
49. Kesselheim AS, Outterson K. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals. Health Aff. 29(9), 1689-1696 (2010).
50. Cressey D. Tiny traits cause big headaches: nanotech medicines held up by lack of particle characterization. Naturenews 467, 264-265 (2010).
51. van Baarlen P, Troost F, van der Meer C et al. Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. Proc. Natl Acad. Sci. DOI: 10.1073/pnas.1000079107 (2010) (Epub ahead of print).
52. Sox HC. Comparative effectiveness research: a progress report. Ann. Intern. Med. 153(7), 469-472(2010).
53. Kotler P, Zaltman G. Social marketing: an approach to planned social change. J. Mark. 85, 3-12 (1971).
54. Glassmeyer ST, Hinchey EK, Boehme SE et al. Disposal practices for unwanted residential medications in the United States. Environ. Int. 35(3), 566-572 (2009).
55. Daughton CG, Ruhoy IS. Accumulation and disposal of leftover medications: a key aspect of pharmEcovigilance. In:An Introduction to Environmental Pharmacology. Rahman SZ, Shahid M, Gupta V (Eds). Ibn Sina Academy, Aligarh, India, 101-107 (2008).
56. Ruhoy IS, Daughton CG. Beyond the medicine cabinet: an analysis of where and why medications accumulate. Environ. Int. 34(8), 1157-1169 (2008). Seminal article examining where, why and how drugs accumulate unused in society.
57. Rosenow ECI. Patients' understanding of and compliance with medications: the sixth vital sign? Mayo Clin. Proc. 80(8), 983-987 (2005).
58. Fincham JE. Patient Compliance with Medications: Issues and Opportunities Pharmaceutical Products Press, The Haworth Press, Inc., Binghamton, NY, USA, 232 (2007).
59. Kleinsinger F. Working with the noncompliant patient. Perm. J. 14(1), 54-60 (2010).
60. Pound P, Britten N, Morgan M et al. Resisting medicines: a synthesis of qualitative studies of medicine taking. Soc. Sci. Med. 61(1), 133-155 (2005).
61. European Parliament. Draft European Parliament Legislative Resolution: proposal for a directive of the European Parliament and of the Council amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use (COM(2008)0665 - C6 0514/2008 - 2008/0260(COD)). Committee on the Environment, Public Health and Food Safety, European Parliament, Strasbourg, Session Document A7-0159/2010, 2010 www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//NONSGML+REPORT+A7-2010- 0159+0+DOC+WORD+V0//EN
62. Gellad WF, Grenard J, McGlynn EA. A Review of Barriers to Medication Adherence: A Framework for Driving Policy Options. RAND Health, RAND Corporation, Santa Monica, CA, USA. TR-765-MVC, 2009 www.rand.org/pubs/ technical-reports/TR765/
63. Proper disposal of prescription drugs. Office of National Drug Control Policy, Executive Office of the President, Washington, DC, USA, 2009 www.whitehousedrugpolicy.gov/publications/pdf/prescrip-disposal.pdf
64. Musson SE. Determination of Selected Pharmaceutical Compounds and Determination of their Fate in Modern Lined Landfills. Doctoral Dissertation, University of Florida, Department of Environment Engineering Sciences, Gainesville, FL, USA, 101, 2006 www.ees.ufl.edu/homepp/townsend/steve-Musson. html
65. Daughton CG. Drugs and the environment: stewardship & sustainability. National Exposure Research Laboratory, Environmental Sciences Division, US EPA, Las Vegas, NV, NERL-LV-ESD 10/081, EPA/600/R-10/106, 12 September, 2010, 196 www.epa.gov/nerlesd1/bios/daughton/APM200-2010.pdf Comprehensive document on disposal of leftover drugs and ramifications for healthcare and the environment.
66. DEA. National Take-Back Initiative. US Department of Justice, Drug Enforcement Administration, Washington, DC, 2010 www.deadiversion.usdoj.gov/ takeback
67. Medicines Recommended for Disposal by Flushing. US Food and Drug Administration, Rockville, MD, USA 2009 (revised March 2010) www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/ EnsuringSafeUseofMedicine/SafeDisposalofMedicines/ucm186187.htm#MEDICINES
68. Krueger BW, Krueger KA. Secondary pentobarbital poisoning of wildlife: pentobarbital-euthanized carcasses are poisonous to scavenging animals. US Fish and Wildlife Service, Fact Sheet, 2007 www.fws.gov/mountain-prairie/poison.pdf
69. Best management practices for unused pharmaceuticals at healthcare facilities - draft for public comment. US Environmental Protection Agency, Washington, DC, USA 2010 http://water.epa.gov/scitech/wastetech/guide/ unusedpharms-index.cfm
70. WHO Model List of Essential Medicines. World Health Organization, Geneva, Switzerland, 16 list (updated), March, 2010 www.who.int/medicines/publications/ essentialmedicines/en/index.html
71. Medicines: rational use of medicines. World Health Organization, Geneva, Switzerland, Fact Sheet No. 338, May 2010 www.who.int/mediacentre/factsheets/ fs338/en/
72. Chambers RG, Mitchell FL. Order more prescription pads: rule change on reimbursement for over-the-counter drugs www.mcguirewoods.com/news-resources/ item.asp?item=5087
73. US FDA. 2009 Importation of Active Pharmaceutical Ingredients Requirements, FD&C Act: Sec. 503. [21 USC §353] Exemptions and Consideration for Certain Drugs, Devices, and Biological Products. www.fda.gov/RegulatoryInformation/Legislation/ FederalFoodDrugandCosmeticActFDCAct/FDCActChapterVDrugsandDevices/ucm108068.htm
74. Klobuchar A, Grassley C, Brown S. S. 3397: Secure and Responsible Drug Disposal Act of 2010: To amend the Controlled Substances Act to provide for take-back disposal of controlled substances in certain instances, and for other purposes. 111th US Congress (2009-2010) www.opencongress.org/bill/111-s3397/show
75. Inslee J, Smith, Stupak, Moran. HR 5809: Safe Drug Disposal Act of 2010. To amend the Controlled Substances Act to provide for take-back disposal of controlled substances in certain instances, and for other purposes. Senate and House of Representatives of the United States of America in Congress, 111th US Congress (2009-2010) www.govtrack.us/congress/bill.xpd?bill=h111-5809
76. BIDMC. OpenNotes. Beth Israel Deaconess Medical Center (BIDMC), Brookline, Massachusetts, USA 2009 http://myopennotes.org/about.shtml
77. US FDA. Overview of CDRH Transparency www.fda.gov/AboutFDA/ CentersOffices/CDRH/CDRHTransparency/ucm199624.htm
78. AHRQ. What is comparative effectiveness research. Agency for Healthcare Research and Quality, US HHS, Rockville, MD, USA 2010 www.effectivehealthcare. ahrq.gov/index.cfm/what-is-comparative-effectivenessresearch1/
79. Journal of Drug Assessment http://informahealthcare.com/page/jda
80. Foster D, Lawson S, Blythe M, Cairns P. Wattsup? Motivating reductions in domestic energy consumption using social networks. Presented at: NordiCHI 2010. Reykjavik, Iceland, 16-20 October 2010 http://eprints.lincoln.ac.uk/3155/
81. Working together to provide the best evidence for health care. The Cochrane Collaboration Oxford and London, UK, 2010 www.cochrane.org
82. Evidence-based practice centers: synthesizing scientific evidence to improve quality and effectiveness in healthcare. Agency for Healthcare Research and Quality, US HHS, Rockville, MD, USA 2010 www.ahrq.gov/clinic/epc/
83. MediaForce. MFPR Announces PharmaNet. MediaForce PR, Fairfax, VA, USA 2010 www.mediaforcepr.com/newsdetail.html
84. Kaye L, Crittenden J, Gressitt S. Reducing prescription drug misuse through the use of a citizen mail-back program in Maine - Safe medicine disposal for ME: a handbook and summary report. The University of Maine, Center on Aging, Bangor, ME, US EPA Grant # CH-83336001-0, April 2010 www.epa.gov/aging/ RX-report-Exe-Sum/
85. Guidelines for drug donations. World Health Organization, Department of Essential Drugs and Other Medicines, Geneva, Switzerland, 1999 (revised) www.drugdonations.org/eng/richtlijnen/eng-guidelinesdrugdonation.pdf
86. Mankes RF. Albany Medical Center. Pharmaceutical Waste Management: a 2 year pilot project www.dos.state.ny.us/watershed/ppt/AMCWestPoint9-16-2008. ppt#256,1, Albany Medical Center
87. Healthy Skepticism: countering misleading health information. Healthy Skepticism Inc., Willunga, Australia, 2010 www.healthyskepticism.org/global/
88. Truthful prescription drug advertising and promotion (bad ad program). Division of Drug Marketing, Advertising, and Communications in the Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA 2010 www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ Surveillance/DrugMarketingAdvertisingandCommunications/ucm209384.htm
89. Drug promotion database. WHO Department of Essential Drugs & Medicines Policy and Health Action International, 2003 www.drugpromo.info/
90. Lever AM. Vending machines for prescription drugs on trial. BBC Health News, 2010 www.bbc.co.uk/news/health-10959457
91. Cook J. Maine Care Providers: Initial Prescription Limits (Phase III). Department of Health and Human Services, MaineCare Services, Augusta, ME, USA, 25 September 2009 www.maine.gov/dhhs/oms/index.shtml
92. Department of Health and Human Services. Preferred Drug List News: Mainecare Initial 15 Day Supply. Pharmacy Benefit Update, Department of Health and Human Services, Augusta, ME, USA, 2009, Fall/Winter Issue www.mainecarepdl.org/uploads/Fc/fi/FcfiTvBbGOnkAzU4YQeHEA/PHARMACY-BENEFIT- UPDATE-Fall-Winter-2009.pdf
93. Enhancing prescription medicine adherence: a national action plan. National Council on Patient Information and Education, Rockville, MD, USA, August 2007 www.talkaboutrx.org/documents/enhancing-prescription-medicine- adherence.pdf
94. Mackridge AJ. Medicines non-use in primary care. Doctoral Dissertation, Aston University, Birmingham, UK, 2005 http://mackridge.com/wp-content/uploads/ 2008/12/complete-thesis-web.pdf
95. Ranger J. Redbridge: warning over bogus medicine collections. East London and West Essex Guardian Series, 20 March 2010 www.guardian-series.co.uk/news/ 5074038.REDBRIDGE--Warning-over-bogus-medicine-collections/